Graves' ophthalmopathy

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

Retrieved on: 
水曜日, 5月 29, 2024
Patient, Learning, Information technology, IPR, Endocrinology, Patent, Calendar, FDA, Teprotumumab, Neonatal Fc receptor, Graves' ophthalmopathy, Autoimmune disease, TED, CIDP, Research, Common stock, Neurology, Hearing loss, Growth factor, Fibroblast growth factor receptor, Pharmaceutical industry

Financial Highlights for Fiscal Fourth Quarter Ended March 31, 2024:

Key Points: 
  • Financial Highlights for Fiscal Fourth Quarter Ended March 31, 2024:
    Cash Position: As of March 31, 2024, Immunovant’s cash and cash equivalents totaled approximately $635 million.
  • Financial Highlights for Fiscal Year Ended March 31, 2024:
    R&D Expenses: Research and development expenses were $212.9 million for the fiscal year ended March 31, 2024, compared to $160.3 million for the fiscal year ended March 31, 2023.
  • G&A Expenses: General and administrative expenses were $57.3 million for the fiscal year ended March 31, 2024, compared to $48.0 million for the fiscal year ended March 31, 2023.
  • Net loss for the fiscal year ended March 31, 2024 and 2023 included $41.1 million and $32.3 million, respectively, related to non-cash stock-based compensation expense.

ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024

Retrieved on: 
水曜日, 5月 29, 2024
ENDO, Private practice, SLRN, Jules Stein Eye Institute, Orbital, Immunoglobulin G, University, FDA, TED, Oculoplastics, Endocrine system, University of California, Graves' ophthalmopathy

LOS ANGELES, May 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED) will be shared as a late breaking oral presentation at the Endocrine Society’s Annual Meeting (ENDO 2024), taking place from June 1-4 in Boston, MA. Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R is the only FDA-approved mechanism of action for the treatment of TED.

Key Points: 
  • LOS ANGELES, May 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED) will be shared as a late breaking oral presentation at the Endocrine Society’s Annual Meeting (ENDO 2024), taking place from June 1-4 in Boston, MA.
  • Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R).
  • Inhibition of IGF-1R is the only FDA-approved mechanism of action for the treatment of TED.
  • Presentation details are as follows:
    Presenter: Dr. Shoaib Ugradar, Department of Orbital and Oculoplastic Surgery, Private Practice; The Jules Stein Eye Institute, University of California

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

Retrieved on: 
木曜日, 5月 16, 2024
Membrane protein, Moyamoya disease, Patient, Pharmacokinetics, TRML, Medical research, Risk, Clinical trial, University, Safety, Stroke, Chronic kidney disease, Senior, MD, Buerger's test, Death, Inflammation, ASCVD, CKD, Medical director, IL-6, Graves' ophthalmopathy, Entrepreneurship, Pharmaceutical industry

NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that the first patient has been dosed in its Phase 2 TRANQUILITY trial, marking the initiation of its clinical development program for TOUR006, a long-acting, fully human, anti-IL-6 monoclonal antibody, for the treatment of atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular diseases. TRANQUILITY is a randomized, double-blind, placebo-controlled trial enrolling patients with inflammatory risk, manifesting as elevated high-sensitivity C-reactive protein (hs-CRP) at baseline, and chronic kidney disease (CKD).

Key Points: 
  • TRANQUILITY is a randomized, double-blind, placebo-controlled trial enrolling patients with inflammatory risk, manifesting as elevated high-sensitivity C-reactive protein (hs-CRP) at baseline, and chronic kidney disease (CKD).
  • If successful, results from the Phase 2 TRANQUILITY trial are expected to position Tourmaline to be Phase 3-ready in 2025 for ASCVD and other cardiovascular diseases.
  • “We believe TRANQUILITY can showcase TOUR006’s potential as a best-in-class treatment in these indications, offering ease of use and enabling consistent patient adherence, thanks to a potential quarterly dosing schedule.
  • We look forward to sharing topline results from TRANQUILITY in the first half of 2025.”

Velocity National Provider Network Welcomes Local Infusion to Network, Making Affordable Infusion Therapy More Accessible

Retrieved on: 
月曜日, 5月 13, 2024
Partnership, Local, Patient, Gout, Practitioner, Infusion, Psoriasis, Multiple sclerosis, Crohn's disease, Velocity, Graves' ophthalmopathy, Rheumatoid arthritis, Inflammatory bowel disease

NASHVILLE, Tenn., May 13, 2024 /PRNewswire-PRWeb/ -- Velocity National Provider Network (VNPN) recently welcomed Local Infusion, an outpatient infusion therapy provider, to its care provider network as part of its ongoing work to expand access to top-tier healthcare services.

Key Points: 
  • Velocity National Provider Network (VNPN) members can receive in-network medication IV therapy at outpatient locations in New Hampshire, Maine, Connecticut and New Jersey
    NASHVILLE, Tenn., May 13, 2024 /PRNewswire-PRWeb/ -- Velocity National Provider Network (VNPN) recently welcomed Local Infusion, an outpatient infusion therapy provider, to its care provider network as part of its ongoing work to expand access to top-tier healthcare services.
  • Velocity National Provider Network (VNPN) proudly announces its partnership with Local Infusion, a leading healthcare provider in the Northeast.
  • "Velocity National Provider Network (VNPN) proudly announces its partnership with Local Infusion, a leading healthcare provider in the Northeast.
  • "We're excited to partner with Velocity National Provider Network as a national provider.

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
木曜日, 5月 9, 2024
Health, Stem Cells, Research, Pharmaceutical, Science, Biotechnology, Investment, Teclistamab, Partnership, Myasthenia gravis, Trial of the century, Growth, Hook effect, ASCO, Journal, Lung cancer, Graves' ophthalmopathy, Pharmacokinetics, National Medical Products Administration, Conference, Fluorouracil, Patent, Telephone, NSCLC, Merck Group, Safety, Pembrolizumab, Artificial intelligence, CEACAM5, Autoimmune disease, Immunology, Monoclonal antibody, Clinical trial, University, TED, Sale, Chicken, Bystander effect, Antigen, Neonatal Fc receptor, Patient, Society, Pharmaceutical industry

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.
  • “The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base.
  • General and administrative expense was $8.3 million for the first quarter of 2024, compared with $8.2 million for the same period in 2023.
  • As of March 31, 2024, OmniAb had cash, cash equivalents and short-term investments of $69.0 million.

ACELYRIN, INC. Announces Leadership Transition

Retrieved on: 
木曜日, 5月 9, 2024
Corporation, Sale, Zymergen, Graves' ophthalmopathy, Immunotherapy, History, Administration, MRCP, Corporate development, IPO, Patient, Synthetic biology, LOS, SLRN, FRCP, Renewable energy, INC, Knowledge, Aviation, Management

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that ACELYRIN’s founder Shao-Lee Lin, M.D., Ph.D. has stepped down as Chief Executive Officer and that Mina Kim, chief legal and administrative officer at ACELYRIN, has been appointed Chief Executive Officer and to the company’s Board of Directors (the “Board”).

Key Points: 
  • Ms. Kim brings more than 20 years of operational and leadership experience across a range of industries including synthetic biology, immunotherapy, renewable energy, and aviation.
  • Ms. Kim played a pivotal role in ACELYRIN’s initial public offering and has served as ACELYRIN’s Chief Legal and Administrative Officer since November 2022.
  • “With encouraging data across our pipeline, we are continuing to advance our core mission of making a meaningful difference for patients.
  • The company will file the related quarterly report on Form 10-Q no later than May 14, 2024.

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

Retrieved on: 
木曜日, 5月 9, 2024
Psoriatic arthritis, Hyperglycemia, Graves' ophthalmopathy, Abscess, Huber loss, Risk, QW, Hidradenitis suppurativa, Conference, Webcast, Suicidal ideation, Development, MRCP, Disease, Patient, Fungus, LOS, SLRN, Diplopia, FRCP, IL-17A, POC, CAS, Quality of life, Exophthalmos, Behavior, Infection, Pharmaceutical industry

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today provided an update on various corporate milestones.

Key Points: 
  • This Phase 2b/3 trial, designed to be the first of two registrational trials in TED, is planned to be initiated in the second half of 2024.
  • Izokibep in Uveitis (UV): ACELYRIN expects to complete enrollment in the ongoing Phase 2b/3 trial this month and top line data are anticipated by year-end 2024.
  • ACELYRIN expects to report cash, cash equivalents, and short-term marketable securities of $678.5 million at March 31, 2024.
  • Gil Labrucherie, who serves as ACELYRIN’s Chief Financial Officer, has also been named Chief Business Officer in addition to Chief Financial Officer.

Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events

Retrieved on: 
木曜日, 5月 9, 2024
Biotechnology, General Health, Pharmaceutical, Health, Graves' ophthalmopathy, Investment, Research, Teprotumumab, License, Partnership, Webcast, TRX, Patient, Glucagon, Access, TED, Amgen, Pharmaceutical industry

Keveyis®: First quarter net revenue remained very strong at $13.1 million – an increase of approximately 3% compared to the same period in 2023.

Key Points: 
  • Keveyis®: First quarter net revenue remained very strong at $13.1 million – an increase of approximately 3% compared to the same period in 2023.
  • Recorlev®: First quarter net revenue was $10.6 million – an increase of $6.1 million compared to the same period in 2023.
  • Cash, cash equivalents, and short-term investments at March 31, 2024 was $87.4 million compared to $72.5 million at December 31, 2023.
  • Xeris will host a conference call and webcast on Thursday, May 9, 2024 at 8:30 a.m. Eastern Time.

Soleo Health Unveils Pharmacy in Jackson, MS; Marks Pharmacy Entry Into State

Retrieved on: 
月曜日, 4月 29, 2024
Professional Services, Other Science, Research, Science, Practice Management, Nursing, Medical Supplies, Other Health, Managed Care, FDA, General Health, Diabetes, Radiology, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Hospitals, Software, Genetics, Fitness & Nutrition, Clinical Trials, Cardiology, Biotechnology, AIDS, Technology, Health, Surgery, Insurance, Ulcerative colitis, Pharmacy, Crohn's disease, Immunodeficiency, Graves' ophthalmopathy, AIC, Alzheimer's disease, Parenteral nutrition, Patient, ALS, Rheumatoid arthritis, Hattiesburg, Mississippi, Medical device

Soleo Health , a national provider of complex specialty pharmacy services, announced today the opening of its latest pharmacy and ambulatory infusion center (AIC) in Ridgeland, Mississippi.

Key Points: 
  • Soleo Health , a national provider of complex specialty pharmacy services, announced today the opening of its latest pharmacy and ambulatory infusion center (AIC) in Ridgeland, Mississippi.
  • The new Soleo Health Jackson location, at 1250 E. County Line Road, Ridgeland, Mississippi, 601.427.4510, is a state-of-the-art pharmacy supporting patients in their homes or at its ambulatory infusion center.
  • Soleo Health Jackson specializes in providing biologic and infusion therapies for patients with complex, rare and ultra-rare diseases and autoimmune disorders.
  • “Soleo Health identified an opportunity to expand its reach in Mississippi by bringing its complex specialty pharmacy services to the marketplace.

ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
木曜日, 3月 28, 2024
Research, IL-17A, Strategic planning, Cell, Exophthalmos, Disease, Infection, Fungus, Risk, Inflammation, SLRN, Patient, Psoriatic arthritis, Acquisition, Doctor of Philosophy, MD, Quality of life, CAS, Senior, IPR, Eye, NeoGenomics, Graves' ophthalmopathy, Suicidal ideation, Behavior, Hidradenitis suppurativa, QW, Drug development, LOS, Corporate communication, Abscess, Diplopia, Pharmaceutical industry

LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the full year ended December 31, 2023 and highlighted recent corporate updates and upcoming milestones.

Key Points: 
  • R&D Expenses: Research and development expenses were $355.9 million for the full year ended December 31, 2023, as compared to $55.6 million for 2022.
  • G&A Expenses: General and administrative expenses were $66.2 million for the full year ended December 31, 2023, as compared to $13.5 million for 2022.
  • Net Loss: Net loss for the full year ended December 31, 2023 was $381.6 million, compared to $64.8 million for 2022.
  • In December 2023, the Company announced the appointment of Lynn Tetrault to its Board of Directors.